[PDF] Top 20 Rev. Bras. Hematol. Hemoter. vol.38 número2
Has 10000 "Rev. Bras. Hematol. Hemoter. vol.38 número2" found on our website. Below are the top 20 most common "Rev. Bras. Hematol. Hemoter. vol.38 número2".
Rev. Bras. Hematol. Hemoter. vol.38 número2
... Although this biomarker has been considered promising in studies con- ducted with adults and newborns, the results obtained by the Brazilian researchers did not identify CD64 as a biomar[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.38 número2
... Need to clarify the cause of hemolysis in case report of newborn with clinically significant hemolytic disease and passive transfer of anti-D from maternal RhIg.[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.38 número2
... Method: Bone marrow samples from patients with multiple myeloma were used to stan- dardize a panel of five probes [1q amplification, 13q14 deletion, 17p deletion, t(4;14), and t(14;16)] [r] ... See full document
8
Rev. Bras. Hematol. Hemoter. vol.38 número2
... As all the experts were professionals working in healthcare services in blood transfusion centers, these results suggest that there is a tendency to give greater importance to items rela[r] ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.38 número2
... Trends in mortality of adult patients diagnosed with myeloid leukemia from 1994 to 2011 in southeastern Brazil.. Instituto Nacional de Câncer José Alencar Gomes da Silva?[r] ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.38 número2
... Figure 1 – Initial staging using fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET/CT) revealed a hypermetabolic lesion with high rate of cell [r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.38 número2
... Test results, however, ruled out primary breast cancer while showing breast plasmacytoma, with lambda chain restriction, plasma cell ratio of 95%, CD138 + and negative for CD56 ( Figure [r] ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.38 número2
... In fact, anti-platelet antibodies were labeled as an ‘unnecessary’ test for the routine evaluation of patients presenting with ITP according to the 2011 guidelines of the American Societ[r] ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.38 número2
... Figure 1 – (A) Coronal T1-weighted magnetic resonance imaging after gadolinium administration showing right temporal leptomeningeal, parenchymal (arrow) and pachymeningeal enhancement; ([r] ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.38 número2
... Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment. Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD, Dahm[r] ... See full document
11
Rev. Bras. Hematol. Hemoter. vol.38 número2
... This study describes the prevalence of anemia, hypertension and diabetes and the overall health status in pre-elderly and elderly subjects enrolled in two primary health care clinics, El[r] ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.38 número2
... To generate lentiviral particles, the construct DNAs were tran- siently introduced into 293FT cells by triple co-transfection with the packaging construct pCMVR8.91 encoding gag, pol, and rev and the pseudotyping ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.38 número2
... As there is no curative therapy, researchers have been investigating new drugs to treat myeloproliferative neoplasms, including l -amino acid oxidase from Calloselasma rhodostoma snake v[r] ... See full document
7
Rev. Bras. Hematol. Hemoter. vol.38 número2
... CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL: diffuse large B-cell lymphoma; BCL-U: B-cell lymphoma, unclassifiable, with features intermediate between DLBCL a[r] ... See full document
7
Rev. Bras. Hematol. Hemoter. vol.38 número2
... When sub-scales were compared, oral symptoms and functional limitations had a greater negative impact on the quality of life of adolescents with sickle cell disease ( p -value <0.001 [r] ... See full document
7
Rev. Bras. Hematol. Hemoter. vol.38 número2
... Clinical evidence of a GvL effect after allo HSCT is suggested by a plateau in relapse risk that is reached 2–5 years following allo HSCT, indicating that a substantial pro- portion of l[r] ... See full document
7
Rev. Bras. Hematol. Hemoter. vol.38 número2
... Oral health-related quality of life of children seeking orthodontic treatment based on child oral health impact profile: a cross-sectional study. Contemp Clin Dent[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.38 número2
... Alternative methods for detecting genetic alterations in multiple myeloma samples. aCGH is an alternative technology to test copy number varia-[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.38 número4
... Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chem[r] ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.38 número4
... et al. The immature platelet fraction is a useful marker for predicting the timing of platelet recovery in patients with cancer after chemotherapy and hematopoietic stem cell transplantation. Int J Lab Hematol. ... See full document
4
temas relacionados